Lund and colleagues accurately mention that simply advocating against current benzodiazepine use in PTSD, without providing alternative strategies, is not an option. Future research is warranted, finding the optimal memory reactivation length may become a great clinical challenge of trial-and-error, as benzodiazepine administration may time-dependently both inhibit and promote forgetting in PTSD. (from the article)